vs
Side-by-side financial comparison of GRI Bio, Inc. (GRI) and Inventiva S.A. (IVA). Click either name above to swap in a different company.
GRI Bio, Inc. is the larger business by last-quarter revenue ($16.0K vs $5.1K, roughly 3.1× Inventiva S.A.). GRI Bio, Inc. runs the higher net margin — -13437.5% vs -961352.9%, a 947915.4% gap on every dollar of revenue.
GRI Bio, Inc. is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for autoimmune, inflammatory, and fibrotic diseases. Its product candidates address unmet medical needs, serving global healthcare markets to deliver improved outcomes for patients with underserved disease indications.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
GRI vs IVA — Head-to-Head
Income Statement — Q1 FY2023 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $16.0K | $5.1K |
| Net Profit | $-2.1M | $-49.0M |
| Gross Margin | — | — |
| Operating Margin | -6175.0% | — |
| Net Margin | -13437.5% | -961352.9% |
| Revenue YoY | — | — |
| Net Profit YoY | -611.9% | — |
| EPS (diluted) | $-15.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 24 | — | $5.1K | ||
| Q1 23 | $16.0K | — | ||
| Q3 22 | $2.0K | — | ||
| Q2 22 | $-1.0K | — | ||
| Q1 22 | $0 | — |
| Q2 24 | — | $-49.0M | ||
| Q1 23 | $-2.1M | — | ||
| Q3 22 | $-351.0K | — | ||
| Q2 22 | $-295.0K | — | ||
| Q1 22 | $-302.0K | — |
| Q2 24 | — | — | ||
| Q1 23 | -6175.0% | — | ||
| Q3 22 | -9300.0% | — | ||
| Q2 22 | 18900.0% | — | ||
| Q1 22 | — | — |
| Q2 24 | — | -961352.9% | ||
| Q1 23 | -13437.5% | — | ||
| Q3 22 | -17550.0% | — | ||
| Q2 22 | 29500.0% | — | ||
| Q1 22 | — | — |
| Q2 24 | — | — | ||
| Q1 23 | $-15.04 | — | ||
| Q3 22 | $-0.39 | — | ||
| Q2 22 | $-0.35 | — | ||
| Q1 22 | $-11.62 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7M | $11.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-3.2M | $-85.4M |
| Total Assets | $2.1M | $42.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | — | $11.0M | ||
| Q1 23 | $1.7M | — | ||
| Q3 22 | $4.7M | — | ||
| Q2 22 | $5.2M | — | ||
| Q1 22 | $2.5M | — |
| Q2 24 | — | $-85.4M | ||
| Q1 23 | $-3.2M | — | ||
| Q3 22 | $-5.7M | — | ||
| Q2 22 | $-5.4M | — | ||
| Q1 22 | $-5.2M | — |
| Q2 24 | — | $42.6M | ||
| Q1 23 | $2.1M | — | ||
| Q3 22 | $5.6M | — | ||
| Q2 22 | $8.0M | — | ||
| Q1 22 | $5.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-579.0K | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | — | — | ||
| Q1 23 | $-579.0K | — | ||
| Q3 22 | $-125.0K | — | ||
| Q2 22 | $2.2M | — | ||
| Q1 22 | $-2.3M | — |
| Q2 24 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | 0.0% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
